Breast Cancer Clinical Trial
Exercise Treatment With Standard Therapy for Metastatic Breast Cancer
Summary
This study will test any good and bad effects of aerobic exercise performed while you are receiving the usual first-line treatment for metastatic breast cancer. The researchers think that exercise helps delay the development of resistance to hormone therapy while slowing the growth of tumors.
Eligibility Criteria
Inclusion Criteria:
Patients with histologically-confirmed, HR-positive (ER and/or PR), HER2-negative metastatic breast cancer (MBC)
Postmenopausal status defined by lack of menses for 2 years, oophorectomy, or medical ovarian suppression
Receiving first line endocrine-based therapy (tamoxifen, aromatase inhibitor, or fulvestrant; concurrent molecular therapy also allowed)
Sedentary (i.e., <60 minutes / week of exercise)
Age >18 years
BMI ≥ 18.5
Cleared for exercise participation as per screening clearance via PAR-Q+
Cleared for study participation as per screening consultation with an MSK Exercise Physiologist
Willingness to comply with all study-related procedures
Patients with "treated and stable" brain lesions of a duration of ≥ 2 months may be enrolled
Exclusion Criteria:
Life expectancy <6 months
Enrollment onto any other therapeutic investigational study
Mental impairment leading to inability to cooperate
Concurrent participation in weight loss or other exercise programs
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
Basking Ridge New Jersey, 07920, United States More Info
Middletown New Jersey, 07748, United States More Info
Montvale New Jersey, 07645, United States More Info
Bronx New York, 10467, United States More Info
Commack New York, 11725, United States More Info
Harrison New York, 10604, United States More Info
New York New York, 10065, United States More Info
Principal Investigator
Uniondale New York, 11553, United States More Info
How clear is this clinincal trial information?